Thanks to its unique profile, Estetrol could address unmet needs in various therapeutic areas such as contraception, menopause, neuroprotection in newborns and wound healing.
Innovative E4-based hormone therapy targeting several major menopausal symptoms
Currently in its last stages of development (Phase III)
Treatment of neonatal hypoxic ischemic encephalopathy (HIE), a life-threatening form of brain injury
Currently under clinical program (Phase I study)
Treatment enabling faster and more effective healing
Positive preclinical data have demonstrated the efficacy of Estetrol for topical application to promote wound healing and support its use in clinic
A fully integrated end-to-end contract development and manufacturing platform designed to service Mithra’s innovative pharmaceutical pipeline as well as to support external parties with their pharmaceutical development and manufacturing needs
Collaborations with external companies for the development and manufacturing of highly complex formulations, such as two long-acting injectable products for MedinCell, an innovative long-acting vaginal ring for VaRi Biosciences as well as the production of nearly 1 million vaginal rings, Myring®
Mainly driven by an out-licensing upfront payment of EUR 44.7 million for Donesta®
Increasing our share of energy from renewable sources to reach around 30% of for our Mithra CDMO
Reduction of our greenhouse gas emissions (20%) and waste production (almost 30%)
To stay at the cutting edge in their field of expertise, our R&D teams attended 9 international scientific congresses and published 8 manuscripts.
In 2022, there were no product recall and 100% successful inspections and audits.
To give our employees the opportunity to develop their knowledge and skills, we have doubled our investment in collaborators training.
To attract and retain talents, we upgraded our employee benefits program by including hospitalization, ambulatory and dental insurance as well as seniority leave.
Our ambition is to embed a responsible sourcing policy in our daily purchase practices.
To achieve this objective, our target is to ensure that 50% of Mithra’s direct and indirect purchases are ethically sourced by 2025.
Compliance and ethical standards training has been systematized for all staff members as part of their onboarding process.
At Mithra, 56% of our collaborators are women. Additionally, our Board of Directors is composed of 55% of women.
As women’s health is at the heart of our mission and because 1 in 8 women in Belgium is affected by breast cancer, it seemed more than obvious for Mithra to renew its participation to support the annual Think Pink campaign.